MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-11-2026
SCYNEXIS Deferred Revenue 2011-2026 | SCYX
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue SCYNEXIS
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 235 K | 1.64 M | 1.19 M | - | - | - | - | 121 K | 257 K | 257 K | 257 K | 449 K | 487 K | 182 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.64 M | 121 K | 508 K |
Quarterly Deferred Revenue SCYNEXIS
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 235 K | 1.76 M | 1.77 M | 1.64 M | 1.64 M | 1.64 M | 1.23 M | 1.08 M | 1.19 M | 2.44 M | 3.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54 K | 121 K | 121 K | 121 K | 121 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 257 K | 449 K | 262 K | 487 K | 487 K | 487 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.23 M | 54 K | 678 K |
Deferred Revenue of other stocks in the Drug manufacturers industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
49 K | - | 7.5 % | $ 6.35 M |  USA |
 |
DURECT Corporation
DRRX
|
545 K | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
27.8 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
85.4 M | - | - | $ 754 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
25 K | $ 5.53 | 2.22 % | $ 82.1 M | USA |
 |
Harrow Health
HROW
|
788 K | $ 30.86 | 0.59 % | $ 1.13 B | USA |
 |
Athenex
ATNX
|
2.82 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
114 K | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
250 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
8.21 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Eagle Pharmaceuticals
EGRX
|
6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
600 K | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
26 M | $ 5.5 | 3.38 % | $ 2.01 B | Canada |
 |
Pacira BioSciences
PCRX
|
102 K | $ 23.0 | 3.09 % | $ 1.06 B | USA |
 |
Solid Biosciences
SLDB
|
10.4 M | $ 6.47 | 6.41 % | $ 566 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
641 K | $ 1.07 | 5.94 % | $ 1.33 M | USA |
 |
Aurora Cannabis
ACB
|
27 M | $ 3.47 | 5.15 % | $ 190 M | Canada |
 |
Tilray
TLRY
|
23.7 M | $ 5.41 | 3.84 % | $ 3.34 B | Canada |
 |
Evolus
EOLS
|
11.5 M | $ 6.59 | 2.49 % | $ 425 M | USA |
 |
Emergent BioSolutions
EBS
|
27.2 M | $ 8.15 | 1.12 % | $ 417 M | USA |
 |
Veru
VERU
|
400 K | $ 2.17 | 2.84 % | $ 31.8 M | USA |
 |
cbdMD
YCBD
|
506 K | $ 0.75 | -0.27 % | $ 3.02 M | USA |
 |
Assertio Holdings
ASRT
|
200 K | $ 23.44 | 0.13 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
2.5 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
1 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
543 K | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
160 K | - | - | $ 1.08 B | USA |
 |
Zomedica Corp.
ZOM
|
368 K | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
172 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
46 K | $ 0.82 | 2.71 % | $ 29.5 M | USA |
 |
China Pharma Holdings
CPHI
|
112 K | $ 0.71 | -0.99 % | $ 3.05 M |  China |
 |
TherapeuticsMD
TXMD
|
523 K | $ 2.08 | 1.96 % | $ 24.1 M | USA |